Galectin Therapeutics Inc.

Galectin Therapeutics is a biotechnology company whose drug development pipeline relies on animal testing to advance its primary investigational compounds. The company’s lead drug candidates, including belapectin (GR-MD-02), are designed to inhibit galectin-3 proteins to treat fibrotic diseases. Preclinical research supporting these candidates, as cited in the company’s regulatory filings and clinical trial documents, explicitly references studies using animal models with genetic modifications, such as galectin-3 “knock-out” mice, to demonstrate therapeutic mechanisms and efficacy. This reliance on animal data is a standard, integral part of its research and development process for new pharmaceuticals.

The company’s clinical trial history, including a Phase 2 extension study (NCT02333955), notes that the rationale for its drug candidates is supported by prior research in animal models showing that genetic knockout of galectin-3 reduces structural deficits in organs like the kidney. This indicates animal testing is not incidental but foundational to its product development. As a clinical-stage biopharmaceutical firm with no marketed products, its entire value proposition is built on preclinical animal data to advance candidates toward human trials.